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We screened a collection of synthetic compounds consisting of natural-product-like substructural motifs
to identify a spirocyclic chromane as a novel antiplasmodial pharmacophore using an unbiased cell-
based assay. The most active spirocyclic compound UCF 201 exhibits a 50% effective concentration
(EC50) of 350 nM against the chloroquine-resistant Dd2 strain and a selectivity over 50 using human liver
HepG2 cells. Our analyses of physicochemical properties of UCF 201 showed that it is in compliance with
Lipinski's parameters and has an acceptable physicochemical proﬁle. We have performed a limited
structure-activity-relationship study with commercially available chromanes preserving the spirocyclic
motif. Our evaluation of stage speciﬁcities of UCF 201 indicated that the compound is early-acting in
blocking parasite development at ring, trophozoite and schizont stages of development as well as
merozoite invasion. SPC is an attractive lead candidate scaffold because of its ability to act on all stages of
parasite's aexual life cycle unlike current antimalarials.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
There are more than 200 million global clinical cases of malaria
resulting in over 600,000 deaths each year (Murray et al., 2012;
World Health Organization et al., 2014). In addition to contrib-
uting signiﬁcantly towards overall childhood mortality in the
poorest nations, the disease is estimated to cause considerable
reduction in economic growth in countries that bear a heavy ma-
laria burden (Gallup and Sachs, 2001). The situation is dire because
widespread prevalence of drug resistant parasites is making most
of the available drugs for treatment to rapidly lose their effective-
ness (Greenwood, 1995; Rieckmann, 2006). Most of the drugs that
are currently being used for malaria treatment were developed
more than 30 years ago, and many are derivatives of older drugs.
Furthermore, only a handful of antimalarials primarily belonging to
three main chemical classes (4- and 8-aminoquinolines, antifolates.
and artemisinin-based agents) are being used for therapyLtd on behalf of Australian Society f(Grimberg and Mehlotra, 2011). While artemisinin-based combi-
nation treatments (ACTs) have played an effective role in control-
ling the disease in many malaria endemic areas, the appearance of
resistant parasites to artemisinin derivatives in wide area of
Southeast Asia encompassing south Vietnam to central Myanmar
underscores the fragility of malaria treatment measures (Cui, 2011;
Miotto et al., 2013; Ashley et al., 2014). Therefore, there is a pressing
need for novel therapeutic options to treat resistant malaria. His-
torically, natural products were the most important source for the
majority of therapeutics, including antimalarials (Li and Vederas,
2009). Quinine and artemisinin and their synthetic derivatives
are prime examples in the malaria ﬁeld (Woodward and Doering,
1944; Klayman, 1985). Current trends in lead discovery are biased
towards high-throughput screening (HTS) of synthetic compound
collections instead of the testing of natural products (NPs). The
complexity of natural product structures are often accompanied by
synthetic challenges and supply problems, whereas compound
collections of commercial sources or “in-house” origin are easily
accessible. Nevertheless, because NPs are known to occupy bio-
logically important chemical space, they continue to be valuable foror Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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of NP-inspired compound libraries is a promising alternative
covering chemical space similar to NPs while being synthetic
tractable (Cordier et al., 2008; Rishton, 2008; Vasilevich et al.,
2012). Critical evaluation of known drugs and NPs has been used
to identify NP-based substructural motifs, termed as “BioCores”
(Kombarov et al., 2010), which have been incorporated into the
scaffolds of a BioDesign synthetic library to increase drug-likeness
of compounds. In an effort to identify novel antimalarial scaffolds
we have screened a subset of the anti-infective BioDesign collection
of the vendor Asinex that incorporates “BioCore” features and
structures (e.g., enriched oxygen and saturated rings), which were
ﬁltered against peroxide bridges that are present in many current
antimalarials. Herein, we report that spirocyclic chromane com-
pounds demonstrate potent antiplasmodial activities with excel-
lent selectivity. Furthermore, we demonstrate that this chemotype
exhibits a cellular mechanism of action distinct from current
antimalarials.2. Materials and methods
2.1. Plasmodium falciparum culture and EC50 determination
Plasmodium falciparum Dd2 and 3D7 strains were maintained at
37 C in 5% CO2 and 95% air using a modiﬁed Trager and Jensen
(Trager and Jensen, 1976) method in RPMI media with L-glutamine
(Invitrogen) and supplemented with 25 mM HEPES, 26 mM
NaHCO3, 2% dextrose, 15 mg/L hypoxanthine (SigmaeAldrich),
25 mg/L gentamicin (Life Technologies), and 0.5% Albumax II (Life
Technologies). Different dilutions of the compound in RPMI 1640
(Life Technologies) from a stock of 10 mM in dimethyl sulfoxide
(DMSO) were added to the culture at a 1% parasitemia and 2% he-
matocrit in 96-well black plates (Santa Cruz Biotechnology).
Maximum DMSO concentration in the culture never exceeded
0.125%. Chloroquine at 1 mM was used as a positive control to
determine the baseline value. Following 72 h incubation at 37 C,
the ability of the compounds to inhibit growth of the parasite was
determined by a SYBR green I-based DNA quantiﬁcation assay
(Bennett et al., 2004; Smilkstein et al., 2004; Johnson et al., 2007).
EC50 was calculated (n ¼ 3) from a dose response curve that was
generated from a concentration range of 0e20 mM using GraphPad
Prism v5.0.Fig. 1. Synthetic Scheme of UCF 201. Starting from commercially availab2.2. Cytotoxicity determination
Compounds were evaluated for cytotoxicity using HepG2 hu-
man hepatoma cells. A 384-well clear bottom plate (Santa Cruz
Biotechnology) was seeded with 2500 cells/well and incubated for
24 h. Serial dilutions (0e40 mM concentration range) of the com-
pound were added to the plate followed by incubation for an
additional 48 h. Viability of cells were assessed by MTS [(3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) cell proliferation assay (CellTiter 96®
Aqueous non-radioactive cell proliferation assay, Promega) (Cory
et al., 1991).
2.3. Physicochemical parameters
The aqueous solubility at pH 7.4 was determined by UVevisible
absorption based method (Avdeef, 2001). The permeability was
assessed by the in vitro double-sink parallel artiﬁcial membrane
permeability assay (Kansy et al., 1998) that is a model for the
passive transport from the gastrointestinal tract into the blood
stream. The microsomal stability (Janiszewski et al., 2001) was
determined in the presence of mouse liver microsomes with or
without NADPH.
2.4. Determination of cellular mechanism of action
P. falciparum Dd2 cultures were tightly synchronized using a
combination of magnetic separation of schizonts (Ribaut et al.,
2008) followed by sorbitol treatment at the early ring stage
(Lambros and Vanderberg, 1979). Inhibitory effects of UCF 201 on
parasite development, merozoite egress and invasion were
analyzed by treating the synchronized culture (1.5% hematocrit and
5% parasitemia) at four different time-points post-merozoite in-
vasion (6, 18, 30, and 42 h post invasion or hpi) at 5EC50 ﬁnal
concentration for a duration of 36 h (or 24 h for treatments at the
42 hpi) under regular culture conditions. Giemsa-stained thin
smears were prepared at 12 h intervals for microscopic evaluations
of the intraerythrocytic maturation of parasite.
2.5. Synthesis of spirocyclic chromane UCF 201
In order to meet the amount of compound needed for in vivo
efﬁcacy studies, hit compound UCF 201 has been prepared “in-
house” (Fig. 1). Compound 1 was synthesized via an acetylation ofle a-naphthol, UCF 201 was synthesized in 6 steps in good yields.
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(Vyawahare et al., 2010). It was then converted to compound 2 by
reﬂuxing with tert-butyl 4-oxopiperidine-1-carboxylate and pyr-
rolidine in methanol, which was then deprotected in dichloro-
methane using triﬂuoroacetic acid to afford compound 3.
Compound 3was then reacted with epoxide 4, which was obtained
from the sulfur-ylide epoxidation of 3,4-diﬂuorobenzaldehyde in
ethanol, to yield compound 5which was subsequently converted to
UCF 201 using sodium borohydride in absolute ethanol.
tert-butyl 4-oxo-3,4-dihydrospiro[benzo[h]chromene-2,4'-
piperidine]-1'-carboxylate (2): A solution of intermediate 1
(Vyawahare et al., 2010) (500 mg, 2.7 mmol), tert-butyl 4-
oxopiperidine-1-carboxylate (536 mg, 2.7 mmol) and pyrroli-
dine (517 mg, 7.2 mmol) in absolute methanol (5 mL) was
reﬂuxed for 8 h under N2. The methanol was removed under
reduced pressure and the residue was puriﬁed by ﬂash chro-
matography (hexanes:EtOAc ¼ 7:1) to afford 2 (908 mg, 92%) as a
yellow solid. Rf (hexanes:EtOAc ¼ 5:1) ¼ 0.37. 1H NMR (400 MHz,
CDCl3) d: 8.40e8.24 (m, 1H), 7.84 (d, J ¼ 8.7 Hz, 1H), 7.82e7.76 (m,
1H), 7.65e7.59 (m, 1H), 7.58e7.50 (m, 1H), 7.40 (d, J ¼ 8.6 Hz, 1H),
3.97 (d, J ¼ 13.5 Hz, 2H), 3.42e3.19 (m, 2H), 2.82 (s, 2H),
2.29e2.14 (m, 2H), 1.70 (s, 2H), 1.47 (s, 9H) ppm. 13C NMR
(101 MHz, CDCl3) d: 191.19, 157.06, 154.78, 137.89, 129.76, 128.14,
126.51, 125.36, 123.24, 121.55, 121.00, 115.20, 79.99, 79.16, 47.80,
39.55, 34.29, 28.55 ppm.
spiro[benzo[h]chromene-2,4'-piperidin]-4(3H)-one (3): A
stirred solution of 2 (1.5 g, 4.0 mmol) in DCM (40 mL) was cooled
to 0 C TFA (13 mL) was then added drop wise and the reaction
mixture was allowed to warm to room temperature. After 2 h, the
reaction was diluted with water (40 mL) and extracted with DCM
(40 mL2). The aqueous layer was basiﬁed to pH 9.0 with 10%
NaOH and then extracted with DCM (40 mL3). The organic layer
was combined, dried with sodium sulfate and concentrated un-
der reduced pressure to afford 3 (1.05 g, 97%) as a brown solid). Rf
(DCM:MeOH ¼ 10:1) ¼ 0.3. 1H NMR (600 MHz, CDCl3) d: 8.37 (d,
J ¼ 8.4 Hz, 1H), 7.82 (d, J ¼ 8.7 Hz, 1H), 7.77 (d, J ¼ 8.1 Hz, 1H),
7.62e7.58 (m, 1H), 7.55e7.50 (m, 1H), 7.37 (d, J ¼ 8.6 Hz, 1H),
3.21e3.12 (m, 2H), 2.98e2.90 (m, 2H), 2.80 (d, J ¼ 1.5 Hz, 2H),
2.22e2.13 (m, 2H), 2.08 (s, 2H), 1.77e1.67 (m, 2H) ppm. 13C NMR
(151 MHz, CDCl3) d: 191.66, 157.29, 137.85, 129.63, 128.04, 126.32,
125.49, 123.44, 121.54, 120.67, 115.14, 79.62, 48.17, 42.13,
35.36 ppm. HRMS (ESI) calcd for C17H18NO2 [MþH]þ: 268.1332,
found: 268.1325.
2-(3,4-diﬂuorophenyl)oxirane (4): Potassium hydroxide
pellets 3.92 mg, 7.0 mmol) was added to a solution of 3,4-
diﬂuorobenzaldehyde (500 mg, 3.5 mmol) and trimethylsulfo-
nium iodide (Me3SI) (1.1 g, 5.4 mmol) in acetonitrile (8 mL) and
water (20 mL). The mixture was stirred at 80 C for 4 h and then
cooled; the acetonitrile was removed by rotatory evaporator. The
residue was treated with a solution of water (20 mL) and sodium
hypochlorite or bleach (5 mL) followed by extraction with diethyl
ether (15 mL3). The organic layer was combined, dried with
sodium sulfate and the solvent was removed under reduced
pressure. The crude was used without further puriﬁcation.
1'-(2-(3,4-diﬂuorophenyl)-2-hydroxyethyl)spiro[benzo[h]
chromene-2,4'-piperidin]-4(3H)-one (5): A solution of 3
(500 mg, 1.8 mmol) and 4 (292 mg, 1.8 mmol) in ethanol (30 mL)
was heated to reﬂux for 18 h. The ethanol was removed under
reduced pressure and the residue was puriﬁed by ﬂash chro-
matography (hexanes:EtOAc ¼ 2:1) to afford 5 (498 mg, 63%) as a
yellow solid. Rf ¼ 0.69 in EtOAc. 1H NMR (600 MHz, CDCl3) d: 8.34
(d, J ¼ 8.3 Hz, 1H), 7.85 (d, J ¼ 8.6 Hz, 1H), 7.80 (d, J ¼ 8.1 Hz, 1H),
7.65e7.60 (m, 1H), 7.55 (t, J ¼ 7.6 Hz, 1H), 7.40 (d, J ¼ 8.7 Hz, 1H),
7.25e7.21 (m, 1H), 7.15e7.09 (m, 1H), 7.08 (d, J ¼ 3.4 Hz, 1H),
4.73e4.69 (m, 1H), 2.97 (t, J ¼ 11.4 Hz, 1H), 2.93e2.86 (m, 1H),2.83 (d, J ¼ 16.1 Hz, 2H), 2.72e2.59 (m, 3H), 2.49e2.43 (m, 1H),
2.31e2.22 (m, 2H), 1.92e1.81 (m, 2H) ppm. 13C NMR (151 MHz,
CDCl3) d: 191.39, 157.16, 150.6 (dd, J ¼ 249.0, 16.2 Hz), 149.8 (dd,
J ¼ 248.2, 12.7 Hz), 139.30 (dd, J ¼ 5.3, 3.5 Hz), 137.93, 129.72,
128.17, 126.43, 125.47, 123.32, 121.75 (dd, J ¼ 6.3, 3.5 Hz) 121.63,
120.91, 117.22 (d, J ¼ 17.2 Hz), 115.26, 114.95 (d, J ¼ 18.0 Hz),
78.79, 68.07, 66.19, 50.63, 47.86, 47.73, 34.78, 34.60 ppm. HRMS
(ESI) calcd for C25H24F2NO3 [MþH]þ: 424.1719, found: 424.1705.
1'-(2-(3,4-diﬂuorophenyl)-2-hydroxyethyl)-3,4-
dihydrospiro[benzo[h]chro-mene-2,4'-piperidin]-4-ol (UCF
201): Sodium borohydride (27 mg, 0.7 mmol) was added to a
solution of 5 (100 mg, 0.23 mmol) in absolute ethanol (2 mL). The
reaction mixture was heated at reﬂux overnight and then cooled.
The ethanol was removed under reduced pressure, the residue
was diluted with water (2 mL) and extracted with ethyl acetate
(5 mL3). The combined organic layer was dried with sodium
sulfate, the solvent was evaporated and the residue was puriﬁed
by ﬂash chromatography (DCM:MeOH ¼ 30:1) to afford
ﬁnal compound 1 (88 mg, 88%) as a white solid. Rf
(DCM:MeOH ¼ 10:1) ¼ 0.37. 1H NMR (600 MHz, CDCl3) d:
8.30e8.18 (m, 1H), 7.83e7.70 (m, 1H), 7.57e7.44 (m, 3H),
7.46e7.34 (m, 1H), 7.26e7.20 (m, 1H), 7.15e7.08 (m, 1H),
7.08e7.02 (m, 1H), 4.93 (t, J ¼ 6.7 Hz, 1H), 4.78e4.59 (m, 1H),
2.99e2.73 (m, 2H), 2.74e2.50 (m, 3H), 2.49e2.35 (m, 1H),
2.22e2.05 (m, 2H), 2.02e1.88 (m, 2H), 1.88e1.62 (m, 2H) ppm. 13C
NMR (151 MHz, CDCl3) d: 150.53 (dd, J ¼ 247.1, 13.6 Hz), 149.73
(dd, J ¼ 248.6, 13.5 Hz), 147.46, 139.43 (dd, J ¼ 4.9, 3.5 Hz), 134.37,
127.68, 126.64, 125.60, 125.49, 125.47, 122.12, 121.75 (dd, J ¼ 6.4,
3.3 Hz), 120.22, 117.97, 117.14 (d, J ¼ 17.2 Hz), 114.90 (d,
J ¼ 17.8 Hz), 73.90, 73.88, 67.95, 66.23, 63.33, 50.89, 50.75, 47.92,
47.78, 41.99, 36.10, 35.84, 34.47, 34.19 ppm. HRMS (ESI) calcd for
C25H26F2NO3 [MþH]þ: 426.1875, found: 426.1861.
2.6. Cytological proﬁling of inhibition mechanisms
Effects of UCF 201 on merozoite egress and invasion were
analyzed using a recently reported high content image-based
assay for malaria parasitemia detection and stage classiﬁca-
tion in a 384-well format (Moon et al., 2013). Sorbitol syn-
chronized cultures (P. falciparum HB3 infected cultures) at
1.5% hematocrit and 5% parasitemia were treated at 42 h post-
merozoite invasion with UCF 201 or reference compounds (N-
acetylglucosamine (GlcNAc), E-64, or artemisinin) each at
10 mM ﬁnal concentration for a duration 24 h under a culture
condition of 37 C in gassed chambers (5% CO2, 1% O2 and 94%
N2). The cultures were then diluted in a staining solution
comprising wheat germ agglutinin-Alexa Fluor 488 conjugate
and Mitotracker Red CMXRos each at 1 nM ﬁnal concentra-
tions, and maintained for 20 min at 37 C to allow for com-
plete incorporation of the dyes. The cultures were further
diluted to a ﬁnal hematocrit of 0.02% in a ﬁxing solution
comprising 4% paraformaldehyde and 5 mg/ml DAPI and left to
stand at room temperature for 10 min. Following a brief
vortex at 1700 rpm for 45 s, and a short spin at 1000 rpm for
1 min, ﬁve image ﬁelds were captured using the Operetta 2.0
automated imaging system (Perkin Elmer) from each assay
well (384-well glass plate, Matrical) with a 40X high numer-
ical aperture objective. Operetta automated high content im-
aging system is equipped with a 50 mM pinwheel array and
images were captured at three wavelengths (405 nM, DAPI;
488 nM, Alexa ﬂuor; and 635 nM, Mitoracker deep red).
2.7. Flow cytometric proﬁling of inhibition
Synchronized P. falciparum Dd2 cultures were treated (5EC50)
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hpi time intervals, ﬁxed in a solution containing 0.04% glutaralde-
hyde in PBS, permeabilized with 0.25% Triton X-100, treated with
RNAse (50 mg/ml) and stained with 10.24 mM YOYO-1 (Bouillon
et al., 2013). Flow cytometry acquisition was performed in BD
Accuri C6 using FL-1 channel (488 nm Laser with 533/30 ﬁlter).
2.8. In vivo efﬁcacy of UCF 201
Female pathogen-free Balb/c mice (8 weeks old, ~25 g, 5 animals
per group) were infected with 1  106 P. berghei ANKA parasitized
RBC (from a donor mouse) by intraperitoneal injection. UCF 201
was formulated in 0.5% hydroxyethylcellulose-0.1% Tween 80 for
oral delivery (0.2 ml/dose). The control group had vehicle only.
Parasitemia was monitored by microscopic evaluations of Giemsa-
stained thin smears of daily superﬁcial temporal vein bleed sam-
plings. This animal study protocol was approved by the Institu-
tional Animal Care and Use Committee at the University of Central
Florida.
3. Results and discussion
To identify novel compounds that interact with cellularTable 1
Activity of the Spirocyclic Chromane Chemotype. Z’ factors of these assays were >0.8.
asynchronous culture at a 1% parasitemia and 2% hematocrit and incubated at 37 C for 7
standard deviation of values are shown. For the cytotoxicity assessment the incubation t
UCF201 Spirocyclic chromane (SPC)
ID Structure Dd2 EC50 (mM) HepG2 EC50 (mM)
6 0.41 ± 0.02 13.4 ± 0.3
7 0.45 ± 0.07 17.4 ± 0.6
8 0.51 ± 0.07 19.4 ± 1.0
9 0.56 ± 0.08 13.3 ± 0.8
10 0.56 ± 0.09 17.3 ± 0.8
11 0.61 ± 0.06 15.3 ± 0.9
12 0.61 ± 0.07 18.4 ± 1.0
13 0.62 ± 0.08 15.4 ± 2.0targets different from those of current antimalarials, we screened
a 594 compound collection containing NP-like structural motifs
(e.g. alkaloids, stereogenic carbons, sp3-rich frameworks, basic
nitrogens and others) lacking the presence of a peroxide bridge
(which is typical for the artemisinin class of antimalarials) from a
natural BioDesign scaffold library. To the best of our knowledge,
no report of screening of such a compound selection for anti-
malarial activities exists. We used an unbiased cell-based screen
utilizing SYBR green I-based DNA quantiﬁcation assay (Bennett
et al., 2004; Smilkstein et al., 2004; Johnson et al., 2007) to
identify antiplasmodial activities. For our primary screen, we
used the chloroquine-resistant Dd2 strain, as our main goal was
to overcome the problem of drug-resistant malaria. For selecting
initial hits, we used a stringent criteria of >75% inhibition of the
parasite growth at 1 mM. We identiﬁed 98 (16%) initial hits from
22 different scaffolds based on this criterion. The half maximal
effective concentration (EC50) values of hits prioritized by this
criteria were determined against both the chloroquine-resiatnt
(Dd2) and chloroquine-sensitive (3D7) strains. UCF 201, which
contains two unique structural elements consisting of a chro-
mane ring and a spirocyclic carbon center belongs to the com-
pound class of spirocyclic chromanes, exhibited antiplasmodial
potency with an EC50 value of 350 nM (Table 1) was among theFor the antimalarial screening different dilutions of compounds were added to an
2 h. Each assay was done in triplicate and repeated at least 3 times (n ¼ 3) and the
ime with compounds was 48 h.
Dd2 EC50 ¼ 0.35 mM ± 0.02
3D7 EC50 ¼ 0.39 mM ± 0.03
HepG2 EC50 ¼ 19.0 mM ± 0.7
ID Structure Dd2 EC50 (mM) HepG2 EC50 (mM)
14 0.85 ± 0.10 19.3 ± 1.3
15 0.62 ± 0.08 19.1 ± 0.7
16 0.67 ± 0.07 16.3 ± 0.7
17 0.75 ± 0.09 13.3 ± 1.1
18 0.87 ± 0.07 19.1 ± 1.1
19 1.04 ± 0.05 16.4 ± 1.1
20 1.07 ± 0.06 18.9 ± 0.9
21 1.18 ± 0.10 15.3 ± 0.8
Table 2
Physicochemical properties of spirocyclic chromane UCF 201.
Property UCF 201
clogP 3.85
Molecular Weight (g/mol) 425.5
Number of H Bond Donor 2
Number of N & O Atoms 4
Polar Surface Area (A2) 52.9
Aqueous Solubility pH 7.4/6.2/5.0(mg/mL) 24.3/>42/>42
Permeability pH 7.4/6.2/5.0 (logPe) <2.9/3.2/3.6
Mouse Microsome Stability (% remaining at 60 min) 15.6
Guidelines:
Aqueous solubility: <10 mg/ml-low; 10e60 mg/ml-moderate; >60-high Reference
permeability (logPe) at pH 7.4/6.2/5.0: Verapamil-HCl -2.7/2.9/3.7; metoprolol-
3.6/4.4/>5.4; rantidine- >5.9/5.1/5.2. Verapamil-HCl is considered highly
permeable, metoprolol is moderately permeable; and rantidine is poorly
permeable. Reference microsomal stability (% remaining at 60 min): Verapamil-
68.8%; Testosterone- 26.1%
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similar or better EC50 values with the chloroquine resistant Dd2
strain compared to the chloroquine sensitive 3D7 line, indicating
that it is not inﬂuenced by the efﬂux mechanism of PfCRT of
chloroquine-resistant strains (Ecker et al., 2012). The cytotoxicity
of UCF 201 was determined in human HepG2 hepatoma cells
using the MTS cell proliferation assay. The EC50 value of UCF 201
in HepG2 cells was 19 mM suggesting an excellent selectivity of
over 50-fold (Table 1).
UCF 201 is in compliance with Lipinski's parameters. The data
as shown in Table 2 suggest that the properties of this compound
are in line with the preferred parameters in respect of distribu-
tion coefﬁcient (clogP), molecular weight, number of hydrogen
bond donors and acceptors, as well as polar surface area. We next
determined the in vitro physiochemical proﬁles of the compound.
The aqueous solubility of UCF 201 was moderate at pH 7.4 with a
value of 24.3 mg/ml (57.1 mM), and even better at lower pH. UCF
201 also exhibited excellent permeability (logPe of <2.9)
compared to reference compounds as assessed by the in vitro
double-sink parallel artiﬁcial membrane permeability assayFig. 2. Activity Proﬁle of UCF 201 on P. falciparum Asexual Stages. The effect of UCF 201 on p
invasion time-points at 5EC50 for 36 h. For the (D) 42 h post-invasion time-point the effe
prepared at 12 h intervals for microscopic evaluations. Microscopic images represent paras(Kansy et al., 1998) that is a model for the passive transport from
the gastrointestinal tract into the blood stream. The microsomal
stability (Janiszewski et al., 2001) of UCF 201 in the presence of
mouse liver microsomes is low (16% remaining at 60 min).
Measurements from the aforementioned assays provided initial
evidence that the spirocyclic compound UCF 201 displayed
acceptable physiochemical proﬁles.
In order to perform an expedient SAR evaluation on various
skeleton motifs of UCF 201, we chose related analogues from
Asinex's compound collections. We tested spirocyclic analogues
(6e21) with an emphasis on the substitutions of the piperidine
nitrogen and the results are summarized in Table 1. An important
observation from this limited SAR reveals that simple phenyl
derivatives are much more tolerated than large aromatics such as
indoles and naphthalenes in terms of potency. Within the
selected phenyl groups, it seems that electron density plays no
signiﬁcant role for antimalarial activities as the EC50 values of the
electron-poor UCF 201 and the electron-rich analogue 7 are only
marginally different from their reference counterpart 6. Mono-
ﬂuoro analogue 13 shows an inferior potency proﬁle to
electron-rich analogues; however, additional ﬂuorine atom
boosts the potency by almost two folds, which indicates that the
lipophilicity, rather than the electron density, may have a sig-
niﬁcant impact on the EC50. Our study also suggests that the
benzo[h]chromane of UCF 201 may be replaced by a simple
chromane scaffold without sacriﬁcing submicromolar antima-
larial activity. Because the role of naphthalene on piperidine ni-
trogen could not be determined by the current SAR study, a
thorough screening with phenyl-derived chromanes is necessary
to better understand such structural features.
To further deﬁne the stage-speciﬁcities and speeds of action
of UCF 201, we investigated its effects on (i) schizont develop-
ment, and (ii) merozoite egress and invasion processes. In this
assay, we treated synchronized cultures with UCF 201 at different
stages of intraerythrocytic developmental cycle and followed its
effect on parasite development by quantifying culture para-
sitemias, and proportions of each parasite stage in culture (early
rings, mid-late rings, trophozoites, and schizonts) microscopi-
cally. As can be seen from Fig. 2, while the control culture ma-
tures through the developmental cycle, UCF 201 blocks
maturation. UCF 201 was early acting in inhibitingarasite life cycle stage progression upon treatment at (A) 6 h, (B) 18 h, or (C) 30 h post-
ct was followed for 24 h after compound addition. Giemsa-stained thin smears were
ite stages after evaluating 1000 infected RBC.
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Fig. 4. Efﬁcacy of UCF 201 in the Mouse Malaria Model. (A) Effect of UCF 201 on the survivability of P. berghei ANKA infected Balb/c mice. (B) Effect of UCF 201 on increase in
parasitemia in the P. berghei ANKA infected mice. The experiments were conducted according to the approved protocol of UCF IACUC committee.
B.F. Roberts et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 85e92 91intraerythrocytic developmental cycle when added at either the
early (Fig. 2A 6 h post invasion) or late (Fig. 2B, 18 h post inva-
sion) ring stages. UCF 201 also exhibited inhibitory activity
against schizont development from the mid-trophozoite stage
(30 hpi) (Fig. 2C). In addition, when added at the late schizont
stage (42-hpi), UCF 201 displayed notable reductions in culture
parasitemias with increased accumulation of free merozoites not
schizonts in the culture (Fig. 3A and B). Artemisinin was used as a
reference antimalarial compound acting on asexual stages and E-
64, a cysteine protease inhibitor, blocking egress (Blackman,
2008). As expected artemisinin exposure at 42 hpi did not
block merozoite egress or invasion, whereas E-64 treatment
blocked egress as evidenced by presence of intracellular schizont.
Detection of extracellular merozoites (Fig. 3B) suggests an
inhibitory effect of UCF 201 on the merozoite invasion process in
a manner similar to that of the reference invasion inhibitor N-
acetylglucosamine (Howard and Miller, 1981). Additionally, we
conducted a ﬂow cytometric analysis of the synchronized para-
site culture following exposure to UCF 201. The 6 hpi culture at
the ring stage was treated with UCF 201 at 5EC50 and aliquots
were withdrawn at 12 h intervals for ﬂow cytrometric analysis
following staining with YOYO-1 dye. As shown in Fig. 3C, the
peaks on the right in control culture at 6 hpi represent singly,
double or triply-infected RBC based on DNA content. Following
maturation of the parasite the peaks merge as DNA content in-
creases. At 42 hpi peaks begin to reappear as reinvasion occurs.
At 54 hpi parasites are at the ring stage of the next growth cycle,
peak height increases, and individual peaks reappear. In contrast,
exposure to UCF 201 and artemisinin at the ring stage of matu-
ration is blocked. Collectively, the above data suggest that UCF
201 may act by inhibiting parasite target(s) that are common to
all major intra-erythrocytic forms of P. falciparum.
To overcome the problems of drug-resistance in malaria, a
major goal is to identify the next-generation of lead compounds
that are acting early on parasite's developmental cycle with novelFig. 3. (A) Effect of UCF 201 on Parasitemia When Treated at the Late Schizont/Segmente
compound. Giemsa stained thin smears were prepared every 12 h for microscopic evaluat
phenotype following 24 h exposure at 42 hpi. Synchronized cultures were exposed to UCF
Effect of UCF 201 on P. falciparum growth by ﬂow cytometric analysis of YOYO-1 labeled cel
Plots represent cell count in y-axis versus FL1 channel representing DNA content.mechanism of action. The majority of the current antimalarial
drugs target the digestive vacuole, mitochondrial electron
transport chain, or apicoplast processes of the parasite (Baggish
and Hill, 2002; Famin and Ginsburg, 2002; Krishna et al., 2004;
Dahl and Rosenthal, 2007). Recent analysis of 10 widely used
antimalarials show that none of the drugs were active in blocking
merozoite invasion, whereas only artemisinin and artesunate
demonstrated signiﬁcant ring stage activity (Wilson et al., 2013).
A major signiﬁcance of our work is that the spirocyclic chromane
scaffold inhibits early cellular processes of the parasite invasion
as well as all development stages of the asexual development of
the parasite. Activity of UCF 201 against the ring stage is note-
worthy given that latent ring stage has been shown to promote
in vitro resistance to dihydroartesunate (Hoshen et al., 2000;
Teuscher et al., 2010). Inhibitory effect of UCF 201 against all
stages of asexual life cycle of the parasite (Fig. 2A and B) makes it
particularly useful for the treatment of acute infection where
rapid clearance is needed. Because UCF 201 acts on all intra-
erythrocytic developmental forms including rings and merozo-
ites, we can predict that the spirocyclic chromane chemotype
action is likely to be distinct from known antimalarial
compounds.
Our evaluation of in vivo antimalarial efﬁcacy of UCF 201 using
the murine malaria model infected with P. berghei ANKA strain
demonstrated that the compound prolonged survivability >1.7
times (12 versus 7 days) compared to the control and delayed the
increase in parasitemia (Fig. 4). The P. berghei mouse model is
quite demanding; requires total clearance of parasites otherwise
fatal parasitaemia recrudesce (Nallan et al., 2005). However,
these results are the proof-of-concept of the utility of spirocyclic
chromanes for malaria therapy. Given that this novel anti-
plasmodial scaffold exhibits excellent selectivity, acceptable
physicochemical properties and broad activity on asexual
developmental stages, we believe it will be a good candidate for
hit to lead optimization.r Stage. Synchronized culture at 42 h post invasion was treated with 5EC50 of the
ions of parasitemia to quantify parasitemia. (B) Confocal plate micrograph of parasite
201 or reference compounds E-64, GlcNac, or artemisinin at 10 mM concentration. (C)
ls. The synchronized culture was exposed to UCF 201 at 6 hpi with 5EC50 of UCF 201.
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